down arrow

Lyra Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US55234L1052
USD
4.50
0.49 (12.22%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
2seventy Bio, Inc.
ATAI Life Sciences NV
Generation Bio Co.
Scilex Holding Co.
Astria Therapeutics, Inc.
Immuneering Corp.
Nuvectis Pharma, Inc.
Acrivon Therapeutics, Inc.
Lyra Therapeutics, Inc.
Regencell Bioscience Holdings Ltd.
Eagle Pharmaceuticals, Inc.
Why is Lyra Therapeutics, Inc. ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
Icon
No Data Found
Is Lyra Therapeutics, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Lyra Therapeutics, Inc.
-57.18%
0.17
4950.24%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
15.34%
EBIT Growth (5y)
-2.81%
EBIT to Interest (avg)
-50.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-7.10
Sales to Capital Employed (avg)
0.06
Tax Ratio
0.04%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
81.44%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.31
EV to EBIT
-0.10
EV to EBITDA
-0.10
EV to Capital Employed
-0.20
EV to Sales
3.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1111.31%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -43 MM

PRE-TAX PROFIT(Q)

Highest at USD -7.04 MM

NET PROFIT(Q)

Highest at USD -7.04 MM

EPS(Q)

Highest at USD -5.51

-13What is not working for the Company
NET SALES(HY)

At USD 0.37 MM has Grown at -67.61%

ROCE(HY)

Lowest at -238.26%

RAW MATERIAL COST(Y)

Grown by 113.77% (YoY

CASH AND EQV(HY)

Lowest at USD 61.52 MM

DEBT-EQUITY RATIO (HY)

Highest at 166.09 %

Here's what is working for Lyra Therapeutics, Inc.
Operating Cash Flow
Highest at USD -43 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Pre-Tax Profit
Highest at USD -7.04 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -7.04 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD -5.51
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Here's what is not working for Lyra Therapeutics, Inc.
Net Sales
At USD 0.37 MM has Grown at -67.61%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Cash and Eqv
Lowest at USD 61.52 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio
Highest at 166.09 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 113.77% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."